# The relationship of polymorphisms in ABCC2 and SLCO1B3 with docetaxel pharmacokinetics and neutropenia: CALGB 60805 (Alliance)

## Metadata
**Authors:** Lionel D Lewis, Antonius A Miller, Kouros Owzar, Robert R Bies, Svetlana Markova, Chen Jiang, Deanna L Kroetz, Merrill J Egorin, Howard L McLeod, Mark J Ratain, The Alliance for Clinical Trials in Oncology
**Journal:** Pharmacogenetics and genomics
**Date:** 2013 Jan
**DOI:** [10.1097/FPC.0b013e32835b16d8](https://doi.org/10.1097/FPC.0b013e32835b16d8)
**PMID:** 23188068
**PMCID:** PMC3647228
**URL:** https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3647228/
**PDF:** [https://pmc.ncbi.nlm.nih.gov/articles/PMC3647228/pdf/nihms-467219.pdf](https://pmc.ncbi.nlm.nih.gov/articles/PMC3647228/pdf/nihms-467219.pdf)

## Abstract

Docetaxel-related neutropenia was associated with polymorphisms in the drug transporters ABCC2 and SLCO1B3 in Japanese cancer patients. We hypothesized that this association is because of reduced docetaxel clearance, associated with polymorphisms in those genes. We studied 64 US cancer patients who received a single cycle of 75 mg/m2 of docetaxel monotherapy. We found that the ABCC2 polymorphism at rs-12762549 trended to show a relationship with reduced docetaxel clearance (P = 0.048), but not with neutropenia. There was no significant association of the SLCO1B3 polymorphisms with docetaxel clearance or neutropenia. We conclude that the relationship between docetaxel-associated neutropenia and polymorphisms in drug transporters identified in Japanese patients was not confirmed in this cohort of US cancer patients.

Keywords: ABCC2 (pharmacogenetics), docetaxel, neutropenia, pharmacokinetics, SLCO1B3

## Acknowledgements

The research for CALGB 60805 and 9871 (Alliance) was supported, in part, by grants from the National Cancer Institute (CA31946) to the Alliance for Clinical Trials in Oncology (Monica M. Bertagnolli, MD, Chair) and to the Alliance Statistical Center (Daniel J. Sargent, PhD, CA33601). The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute.

Support for this study also came from CA31956, CA 44691, CA23108, GM61393, EB001975, and the Pharmacogenetics Research Network to Dr Deanna L. Kroetz (GM61390) and Dr Mark J. Ratain (GM61393).

The following institutions participated in this study: Duke University Medical Center, Durham, NC, Jeffrey Crawford, MD, supported by CA47577; Memorial Sloan-Kettering Cancer Center, New York, NY, Clifford A. Hudis, MD, supported by CA77651; Roswell Park Cancer Institute, Buffalo, NY, Ellis Levine, MD, supported by CA59518; Southeast Cancer Control Consortium Inc. CCOP, Goldsboro, NC, James N. Atkins, MD, supported by CA45808; State University of New York Upstate Medical University, Syracuse, NY, Stephen L. Graziano, MD, supported by CA21060; The Ohio State University Medical Center, Columbus, OH, Clara D. Bloomfield, MD, supported by CA77658; University of California at San Diego, San Diego, CA, Barbara A. Parker, MD, supported by CA11789; University of Texas Southwestern Medical Center, Dallas, TX, supported by CA37347; University of California at San Francisco, San Francisco, CA, Charles J. Ryan, MD, supported by CA60138; University of Chicago, Chicago, IL, Hedy L. Kindler, MD, supported by CA41287; University of Maryland Greenebaum Cancer Center, Baltimore, MD, Martin Edelman, MD, supported by CA31983; Wake Forest University School of Medicine, Winston-Salem, NC, David D. Hurd, MD, supported by CA03927.

## Footnotes

## References

1. Fulton B, Spencer CM. Docetaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of metastatic breast cancer. Drugs. 1996;51:1075–1092. doi: 10.2165/00003495-199651060-00011.  [DOI](https://doi.org/10.2165/00003495-199651060-00011) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/8736622/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Drugs&title=Docetaxel.%20A%20review%20of%20its%20pharmacodynamic%20and%20pharmacokinetic%20properties%20and%20therapeutic%20efficacy%20in%20the%20management%20of%20metastatic%20breast%20cancer&author=B%20Fulton&author=CM%20Spencer&volume=51&publication_year=1996&pages=1075-1092&pmid=8736622&doi=10.2165/00003495-199651060-00011&)

2. Eisenhauer EA, Vermorken JB. The taxoids. Comparative clinical pharmacology and therapeutic potential. Drugs. 1998;55:5–30. doi: 10.2165/00003495-199855010-00002.  [DOI](https://doi.org/10.2165/00003495-199855010-00002) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/9463787/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Drugs&title=The%20taxoids.%20Comparative%20clinical%20pharmacology%20and%20therapeutic%20potential&author=EA%20Eisenhauer&author=JB%20Vermorken&volume=55&publication_year=1998&pages=5-30&pmid=9463787&doi=10.2165/00003495-199855010-00002&)

3. Baker SD, Sparreboom A, Verweij J. Clinical pharmacokinetics of docetaxel: recent developments. Clin Pharmacokinet. 2006;45:235–252. doi: 10.2165/00003088-200645030-00002.  [DOI](https://doi.org/10.2165/00003088-200645030-00002) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/16509758/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Clin%20Pharmacokinet&title=Clinical%20pharmacokinetics%20of%20docetaxel:%20recent%20developments&author=SD%20Baker&author=A%20Sparreboom&author=J%20Verweij&volume=45&publication_year=2006&pages=235-252&pmid=16509758&doi=10.2165/00003088-200645030-00002&)

4. Eichelbaum M, Burk O. CYP3A genetics in drug metabolism. Nat Med. 2001;7:285–287. doi: 10.1038/85417.  [DOI](https://doi.org/10.1038/85417) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/11231620/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Nat%20Med&title=CYP3A%20genetics%20in%20drug%20metabolism&author=M%20Eichelbaum&author=O%20Burk&volume=7&publication_year=2001&pages=285-287&pmid=11231620&doi=10.1038/85417&)

5. Smith NF, Acharya MR, Desai N, Figg WD, Sparreboom A. Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel. Cancer Biol Ther. 2005;4:815–818. doi: 10.4161/cbt.4.8.1867.  [DOI](https://doi.org/10.4161/cbt.4.8.1867) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/16210916/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Cancer%20Biol%20Ther&title=Identification%20of%20OATP1B3%20as%20a%20high-affinity%20hepatocellular%20transporter%20of%20paclitaxel&author=NF%20Smith&author=MR%20Acharya&author=N%20Desai&author=WD%20Figg&author=A%20Sparreboom&volume=4&publication_year=2005&pages=815-818&pmid=16210916&doi=10.4161/cbt.4.8.1867&)

6. Bardelmeijer HA, Ouwehand M, Buckle T, Huisman MT, Schellens JH, Beijnen JH, van Tellingen O. Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir. Cancer Res. 2002;62:6158–6164.  [PubMed](https://pubmed.ncbi.nlm.nih.gov/12414642/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Cancer%20Res&title=Low%20systemic%20exposure%20of%20oral%20docetaxel%20in%20mice%20resulting%20from%20extensive%20first-pass%20metabolism%20is%20boosted%20by%20ritonavir&author=HA%20Bardelmeijer&author=M%20Ouwehand&author=T%20Buckle&author=MT%20Huisman&author=JH%20Schellens&volume=62&publication_year=2002&pages=6158-6164&pmid=12414642&)

7. Huisman MT, Chhatta AA, van Tellingen O, Beijnen JH, Schinkel AH. MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid. Int J Cancer. 2005;116:824–829. doi: 10.1002/ijc.21013.  [DOI](https://doi.org/10.1002/ijc.21013) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/15849751/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Int%20J%20Cancer&title=MRP2%20(ABCC2)%20transports%20taxanes%20and%20confers%20paclitaxel%20resistance%20and%20both%20processes%20are%20stimulated%20by%20probenecid&author=MT%20Huisman&author=AA%20Chhatta&author=O%20van%20Tellingen&author=JH%20Beijnen&author=AH%20Schinkel&volume=116&publication_year=2005&pages=824-829&pmid=15849751&doi=10.1002/ijc.21013&)

8. Kiyotani K, Mushiroda T, Kubo M, Zembutsu H, Sugiyama Y, Nakamura Y. Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel-induced leucopenia. Cancer Sci. 2008;99:967–972. doi: 10.1111/j.1349-7006.2008.00765.x.  [DOI](https://doi.org/10.1111/j.1349-7006.2008.00765.x) | [PMC free article](/articles/PMC11159748/) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/18294295/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Cancer%20Sci&title=Association%20of%20genetic%20polymorphisms%20in%20SLCO1B3%20and%20ABCC2%20with%20docetaxel-induced%20leucopenia&author=K%20Kiyotani&author=T%20Mushiroda&author=M%20Kubo&author=H%20Zembutsu&author=Y%20Sugiyama&volume=99&publication_year=2008&pages=967-972&pmid=18294295&doi=10.1111/j.1349-7006.2008.00765.x&)

9. Lewis LD, Miller AA, Rosner GL, Dowell JE, Valdivieso M, Relling MV, et al. Cancer and Leukemia Group B. A comparison of the pharmacokinetics and pharmacodynamics of docetaxel between African-American and Caucasian cancer patients: CALGB 9871. Clin Cancer Res. 2007;13:3302–3311. doi: 10.1158/1078-0432.CCR-06-2345.  [DOI](https://doi.org/10.1158/1078-0432.CCR-06-2345) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/17545536/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Clin%20Cancer%20Res&title=Cancer%20and%20Leukemia%20Group%20B.%20A%20comparison%20of%20the%20pharmacokinetics%20and%20pharmacodynamics%20of%20docetaxel%20between%20African-American%20and%20Caucasian%20cancer%20patients:%20CALGB%209871&author=LD%20Lewis&author=AA%20Miller&author=GL%20Rosner&author=JE%20Dowell&author=M%20Valdivieso&volume=13&publication_year=2007&pages=3302-3311&pmid=17545536&doi=10.1158/1078-0432.CCR-06-2345&)

10. Bruno R, Vivler N, Vergniol JC, De Phillips SL, Montay G, Sheiner LB. A population pharmacokinetic model for docetaxel (Taxotere): model building and validation. J Pharmacokinet Biopharm. 1996;24:153–172. doi: 10.1007/BF02353487.  [DOI](https://doi.org/10.1007/BF02353487) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/8875345/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=J%20Pharmacokinet%20Biopharm&title=A%20population%20pharmacokinetic%20model%20for%20docetaxel%20(Taxotere):%20model%20building%20and%20validation&author=R%20Bruno&author=N%20Vivler&author=JC%20Vergniol&author=SL%20De%20Phillips&author=G%20Montay&volume=24&publication_year=1996&pages=153-172&pmid=8875345&doi=10.1007/BF02353487&)

11. Hirouchi M, Suzuki H, Itoda M, Ozawa S, Sawada J, Ieiri I, et al. Characterization of the cellular localization, expression level, and function of SNP variants of MRP2/ABCC2. Pharm Res. 2004;21:742–748. doi: 10.1023/b:pham.0000026422.06207.33.  [DOI](https://doi.org/10.1023/b:pham.0000026422.06207.33) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/15180328/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Pharm%20Res&title=Characterization%20of%20the%20cellular%20localization,%20expression%20level,%20and%20function%20of%20SNP%20variants%20of%20MRP2/ABCC2&author=M%20Hirouchi&author=H%20Suzuki&author=M%20Itoda&author=S%20Ozawa&author=J%20Sawada&volume=21&publication_year=2004&pages=742-748&pmid=15180328&doi=10.1023/b:pham.0000026422.06207.33&)

12. Schwarz UI, Meyer zu Schwabedissen HE, Tirona RG, Suzuki A, Leake BF, Mokrab Y, et al. Identification of novel functional organic anion-transporting polypeptide 1B3 polymorphisms and assessment of substrate specificity. Pharmacogenet Genomics. 2011;21:103–114. doi: 10.1097/FPC.0b013e328342f5b1.  [DOI](https://doi.org/10.1097/FPC.0b013e328342f5b1) | [PMC free article](/articles/PMC3044558/) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/21278621/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Pharmacogenet%20Genomics&title=Identification%20of%20novel%20functional%20organic%20anion-transporting%20polypeptide%201B3%20polymorphisms%20and%20assessment%20of%20substrate%20specificity&author=UI%20Schwarz&author=HE%20Meyer%20zu%20Schwabedissen&author=RG%20Tirona&author=A%20Suzuki&author=BF%20Leake&volume=21&publication_year=2011&pages=103-114&pmid=21278621&doi=10.1097/FPC.0b013e328342f5b1&)

13. Baker SD, Verweij J, Cusatis GA, van Schaik RH, Marsh S, Orwick SJ, et al. Pharmacogenetic pathway analysis of docetaxel elimination. Clin Pharmacol Ther. 2009;85:155–163. doi: 10.1038/clpt.2008.95.  [DOI](https://doi.org/10.1038/clpt.2008.95) | [PMC free article](/articles/PMC4612590/) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/18509327/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Clin%20Pharmacol%20Ther&title=Pharmacogenetic%20pathway%20analysis%20of%20docetaxel%20elimination&author=SD%20Baker&author=J%20Verweij&author=GA%20Cusatis&author=RH%20van%20Schaik&author=S%20Marsh&volume=85&publication_year=2009&pages=155-163&pmid=18509327&doi=10.1038/clpt.2008.95&)

14. Chew SC, Singh O, Chen X, Ramasamy RD, Kulkarni T, Lee EJ, et al. The effects of CYP3A4, CYP3A5, ABCB1, ABCC2, ABCG2 and SLCO1B3 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of docetaxel in nasopharyngeal carcinoma patients. Cancer Chemother Pharmacol. 2011;67:1471–1478. doi: 10.1007/s00280-011-1625-9.  [DOI](https://doi.org/10.1007/s00280-011-1625-9) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/21468756/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Cancer%20Chemother%20Pharmacol&title=The%20effects%20of%20CYP3A4,%20CYP3A5,%20ABCB1,%20ABCC2,%20ABCG2%20and%20SLCO1B3%20single%20nucleotide%20polymorphisms%20on%20the%20pharmacokinetics%20and%20pharmacodynamics%20of%20docetaxel%20in%20nasopharyngeal%20carcinoma%20patients&author=SC%20Chew&author=O%20Singh&author=X%20Chen&author=RD%20Ramasamy&author=T%20Kulkarni&volume=67&publication_year=2011&pages=1471-1478&pmid=21468756&doi=10.1007/s00280-011-1625-9&)

15. Bosch TM, Huitema AD, Doodeman VD, Jansen R, Witteveen E, Smit WM, et al. Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel. Clin Cancer Res. 2006;12:5786–5793. doi: 10.1158/1078-0432.CCR-05-2649.  [DOI](https://doi.org/10.1158/1078-0432.CCR-05-2649) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/17020985/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Clin%20Cancer%20Res&title=Pharmacogenetic%20screening%20of%20CYP3A%20and%20ABCB1%20in%20relation%20to%20population%20pharmacokinetics%20of%20docetaxel&author=TM%20Bosch&author=AD%20Huitema&author=VD%20Doodeman&author=R%20Jansen&author=E%20Witteveen&volume=12&publication_year=2006&pages=5786-5793&pmid=17020985&doi=10.1158/1078-0432.CCR-05-2649&)

16. Zamboni WC, Combest AJ, Deloia JA, Edwards RP, Bridges AS, Zamboni BA, et al. Pharmacologic and phenotypic study of docetaxel in patients with ovarian or primary peritoneal cancer. Cancer Chemother Pharmacol. 2011;68:1255–1262. doi: 10.1007/s00280-011-1609-9.  [DOI](https://doi.org/10.1007/s00280-011-1609-9) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/21437702/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Cancer%20Chemother%20Pharmacol&title=Pharmacologic%20and%20phenotypic%20study%20of%20docetaxel%20in%20patients%20with%20ovarian%20or%20primary%20peritoneal%20cancer&author=WC%20Zamboni&author=AJ%20Combest&author=JA%20Deloia&author=RP%20Edwards&author=AS%20Bridges&volume=68&publication_year=2011&pages=1255-1262&pmid=21437702&doi=10.1007/s00280-011-1609-9&)

17. de Graan AJ, Lancaster CS, Obaidat A, Hagenbuch B, Elens L, Friberg LE, et al. Influence of polymorphic OATP1B-type carriers on the disposition of docetaxel. Clin Cancer Res. 2012;18:4433–4440. doi: 10.1158/1078-0432.CCR-12-0761.  [DOI](https://doi.org/10.1158/1078-0432.CCR-12-0761) | [PMC free article](/articles/PMC3464009/) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/22711709/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Clin%20Cancer%20Res&title=Influence%20of%20polymorphic%20OATP1B-type%20carriers%20on%20the%20disposition%20of%20docetaxel&author=AJ%20de%20Graan&author=CS%20Lancaster&author=A%20Obaidat&author=B%20Hagenbuch&author=L%20Elens&volume=18&publication_year=2012&pages=4433-4440&pmid=22711709&doi=10.1158/1078-0432.CCR-12-0761&)

18. Tran A, Jullien V, Alexandre J, Rey E, Rabillon F, Girre V, et al. Pharmacokinetics and toxicity of docetaxel: role of CYP3A, MDR1, and GST polymorphisms. Clin Pharmacol Ther. 2006;79:570–580. doi: 10.1016/j.clpt.2006.02.003.  [DOI](https://doi.org/10.1016/j.clpt.2006.02.003) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/16765145/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Clin%20Pharmacol%20Ther&title=Pharmacokinetics%20and%20toxicity%20of%20docetaxel:%20role%20of%20CYP3A,%20MDR1,%20and%20GST%20polymorphisms&author=A%20Tran&author=V%20Jullien&author=J%20Alexandre&author=E%20Rey&author=F%20Rabillon&volume=79&publication_year=2006&pages=570-580&pmid=16765145&doi=10.1016/j.clpt.2006.02.003&)
